Hyperlipidemia

References

• Vital statistics of the United States: 1988. Vol II. Mortality, Part B, 1988. Hyattsville, MD: National Center for Health Statistics, 1990
   Google Scholar
• The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984: 251(3): 351–64
   PubMed Web of Science ®Google Scholar
• Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987: 317(20): 1237–45
   PubMed Web of Science ®Google Scholar
• Manninen V, Elo MO, Frick MH, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988: 260(5): 641–51
   PubMed Web of Science ®Google Scholar
• Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986: 8(6): 1245–55
   PubMed Web of Science ®Google Scholar
• Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988: 223(5): 405–18
   PubMed Web of Science ®Google Scholar
• Brensike JF, Levy RI, Kelsey SF, et al. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study. Circulation 1984: 69(2): 313–24
   PubMed Web of Science ®Google Scholar
• Arntzenius AC, Kromhout D, Barth JD, et al. Diet, lipoproteins, and the progression of coronary atherosclerosis: the Leiden Intervention Trial. N Engl J Med 1985: 312(13): 805–11
   PubMed Web of Science ®Google Scholar
• Blankenhorn DH, Nessim SA, Johnson RL, et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987: 257(23): 3233–40 [erratum, JAMA 1988: 259(18): 2698]
   PubMed Web of Science ®Google Scholar
• Buchwald H, Varco RL, Matts JP, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia: report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 1990: 323(14): 946–55
   PubMed Web of Science ®Google Scholar
• Ornish D, Brown SE, Scherwitz LW, et al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet 1990: 336(8708): 129–33
   PubMed Web of Science ®Google Scholar
• Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990: 323(19): 1289–98
   PubMed Web of Science ®Google Scholar
• Kane JP, Malloy MJ, Ports TA, et al. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990: 264(23): 3007–12
   PubMed Web of Science ®Google Scholar
• Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch Intern Med 1988: 148(1): 36–69
   PubMed Web of Science ®Google Scholar
• Witztum JL. Current approaches to drug therapy for the hypercholesterolemic patient. Circulation 1989: 80(5): 1101–14
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Lewis B, Rifkind BM. The value of lowering cholesterol after myocardial infarction. N Engl J Med 1990: 323(16): 1112–9
   PubMed Web of Science ®Google Scholar
• Peters WL. Drug therapy to lower cholesterol. Pract Cardiol 1988: May: 38–47
   Google Scholar
• Peters WL, Goroll AH. The evaluation and treatment of hypercholesterolemia in primary care practice. J Gen Intern Med 1986: 1(3): 183–95
   PubMed Web of Science ®Google Scholar
• Etchason JA, Miller TD, Squires RW, et al. Niacin-induced hepatitis: a potential side effect with low-dose time-release niacin. Mayo Clin Proc 1991: 66(1): 23–8
   PubMed Web of Science ®Google Scholar
• Illingworth DR. Lipid-lowering drugs: an overview of indications and optimum therapeutic use. Drugs 1987: 33(3): 259–79
   PubMed Web of Science ®Google Scholar
• Grundy SM, Goodman DW, Rifkind BM, et al. The place of HDL in cholesterol management: a perspective from the National Cholesterol Educational Program. Arch Intern Med 1989: 149(3): 505–10 [erratum, Arch Intern Med 1989: 149(4): 940]
   PubMedGoogle Scholar
• Grundy SM. Management of hyperlipidemia of kidney disease. Kidney Int 1990: 37(3): 847–53
   PubMed Web of Science ®Google Scholar
• Garg A, Grundy SM. Lovastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus. N Engl J Med 1988: 318(2): 81–6
   PubMed Web of Science ®Google Scholar
• Bradford RH, Shear CL, Chremos AN, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 1991: 151(1): 43–9
   PubMedGoogle Scholar
• Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990: 264(1): 71–5
   PubMed Web of Science ®Google Scholar
• Tobert JA. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol 1988: 62(15): 28–34J
   PubMed Web of Science ®Google Scholar
• Hunninghake DB. Drug treatment of dyslipoproteinemia. Endocrinol Metab Clin North Am 1990: 19(2): 345–60
   PubMed Web of Science ®Google Scholar
• Parthasarathy S, Young SG, Witztum JL, et al. Probucol inhibits oxidative modification of low density lipoprotein. J Clin Invest 1986: 77(2): 641–4
   PubMed Web of Science ®Google Scholar
• Walldius G, Carlson LA, Erikson U, et al. Development of femoral atherosclerosis in hypercholesterolemic patients during treatment with cholestyramine and probucol/placebo: Probucol Quantitative Regression Swedish Trial (PQRST). A status report. Am J Cardiol 1988: 62(3): 37–43B
   Web of Science ®Google Scholar
• Castelli WP. The triglyceride issue: a view from Framingham. Am Heart J 1986: 112(2): 432–7
   PubMed Web of Science ®Google Scholar
• Phillipson BE, Rothrock DW, Connor WE, et al. Reduction of plasma lipids, lipoproteins, and apoproteins by dietary fish oils in patients with hypertriglyceridemia. N Engl J Med 1985: 312(19): 1210–6
   PubMed Web of Science ®Google Scholar
• Harris WS. Fish oils and plasma lipid and lipoprotein metabolism in humans: a critical review. J Lipid Res 1989: 30(6): 785–807
   PubMed Web of Science ®Google Scholar
• Schectman G, Kaul S, Cherayil GD, et al. Can the hypotriglyceridemic effect of fish oil concentrate be sustained? Ann Intern Med 1989: 110(5): 346–52
   PubMed Web of Science ®Google Scholar